Central Nervous System

Biohaven Completes Enrollment of Rimegepant in Second Pivotal Phase 3 Clinical Trial for the treatment of Migraine Biohaven Pharmaceutical has recently announced the completion of enrollment of their study BHV3000-302 in Phase 3. The company is examining the safety and efficacy of Rimegepant for the treatment of Migraine. GSK to integrate Owlstone Medical’s Breath Biopsy Platform into their Clinical Trial Owlstone Medical has announced that GSK will incorporate Owlstone Medical’s Breath Biopsy platform into their clinical development programme of Danirixin. It is a novel drug candidate in its respiratory disease pipeline. Teligent has recently got the First FDA Generi...